Just One Dose of Magic Mushroom Compound Regrows Lost Brain Connections in Mice
Science Alert, 06 July, 2021
Psilocybin, the active psychedelic compound, has some curious effects on the human brain.
Psychedelic IPOs build momentum as Atai Life Sciences goes public
PitchBook, 18 June, 2021
Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange.
My team’s research shows magic mushrooms treat depression, but undoing the stigma will be a bigger challenge
iNews, 03 June, 2021
Bringing psychedelic therapy into mainstream treatment will present some major challenges.
Magic mushroom microdosing: Kiwis call for 'life-saving' treatment to be legalised | Newshub Nation
Newshub, 01 June, 2021
Everyday Kiwis with devastating illnesses are turning to small doses of psychedelic medicines to find relief and are calling for a ‘life-saving’ treatment to be made legal for medical purposes.
Ketamine a game changer in treating eating disorders
Toronto Sun, 29 May, 2021
Ketamine, MDMA and psilocybin are proving useful with treatment-resistant mental illnesses, including eating disorders.
Magic mushroom microdosing: Sick Kiwis call for 'life-saving' Class-A drug to be legalised
Newshub, 29 May, 2021
Every day Kiwis with devastating illnesses are turning to small doses of psychedelics to find relief and are calling for what they call a ‘life-saving’ treatment to be made legal for medical purposes.
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
Globe News Wire, 27 May, 2021
Algernon recently established a clinical research program for the treatment of stroke focused on DMT.
Could the ‘spirit molecule’ be a treatment option for stroke?
Vancouver Sun, 25 May, 2021
Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test.
Who’s in Charge of Psilocybin?
Chacruna, 10 May, 2021
From clinicians and investors to Indigenous groups and activists, debate is raging over whether psychedelics are spiritual tools, new psychiatric drugs, medicines for social change, or all of the above.
Psychedelic medicine is about to blow up
Fast Company, 11 May, 2021
New clinical data shows that MDMA-assisted therapy can have a significant impact on PTSD, paving the way for FDA approval and commercialization.
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
The New York Times, 09 May, 2021
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Legalise 'magic mushrooms' to help cure depression, says London scientist
My London, 06 May, 2021
The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD
Maps.org, 03 May, 2021
The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
There Is a Lot of Fungus Among Us
The New York Times, 24 April, 2021
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.
Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics
The Crimson, 23 April, 2021
Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.
Psychedelics are transforming the way we understand depression and its treatment
The Guardian, 20 April, 2021
Psychiatry has long failed to explain depression. Our research into psilocybin suggests a new approach could offer answers.
Psilocybin least as good as antidepressant in UK study
Reuters, 15 April, 2021
A study published in the New England Journal of Medicine, psilocybin could be as effective as a leading antidepressant—and while more research is still required, the study’s lead author says the results should give people hope for functional alternatives to SSRIs.
New $6.4M research program to advance psychedelics research and treatments
Eurek Alert, 30 March, 2021
Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF).
Suing the DEA for Access to Psilocybin
Mushroom Revival, 24 March, 2021
A Seattle based doctor, Dr. Sunil Aggarwal, has filed a lawsuit against the DEA for denying him permission to use psilocybin therapy in his palliative care.
Psychedelic for meth users: Sydney trial aims to conquer addiction
Sydney Morning Herald, 22 March, 2021
A world-first clinical trial in Sydney aims to find out if giving psychedelics to people who use methamphetamines can help conquer their addiction.
Researchers at St Vincent’s Hospital in Darlinghurst will use psilocybin to turbocharge therapy for patients dependent on “meth” or “ice”.
Can Magic Mushrooms Heal Us?
The New York Times, 18 March, 2021
A very promising mental health experiment is taking shape in Oregon.
‘Better treatments’: Government to fund psychedelic drugs trials to treat mental illness
Sydney Morning Herald, 17 March, 2021
Clinical trials using magic mushrooms, ecstasy and other psychedelic drugs in potential breakthrough therapies for debilitating mental illnesses will be funded by the Australian federal government as part of global efforts to advance innovative treatments. The Morrison government launched a $15 million competitive grant round to kick-start Australian clinical trials of potential breakthrough combination therapies.
Psychedelic therapy could 'reset' depressed brain
BBC News, 16 March, 2021
A powerful hallucinogenic medicine known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time.
New Legion Veterans Village in Surrey will include centre to research medical psychedelics
Small Caps, 13 March, 2021
Surrey will soon be home to a research centre that brings together experts in medical cannabis and psychedelics to help people with post-traumatic stress disorder.
Creso Pharma Acquisition of Psychedelic Company Halucenex Life Sciences Inc.
Vancouver Sun, 15 March, 2021
Creso Pharma (ASX: CPH) has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics company, Halucenex Life Sciences Inc.
Greens MP hopes Canberra will be the first to introduce psychedelic assisted therapy
The Canberra Times, 07 March, 2021
ACT Greens’ MLA Johnathan Davis wants Canberra to be the first jurisdiction to provide an accessible path for psychiatrists to prescribe psychedelic-assisted therapy to patients experiencing serious mental concerns.
NYU is Launching a Center for Psychedelic Medicine
Freethink, 07 March, 2021
NYU’s Langone Health joins the research renaissance.
Study Reveals More People are Using Psychedelics to Self-Treat Mental Health
Vice, 05 March, 2021
The use of psychedelic medicines as an underground self-treatment for mental health conditions is on the rise, according to the world’s largest drug survey, with thousands of people turning to substances like LSD, MDMA, psilocybin and ketamine to treat psychiatric illnesses and emotional distress.
Why the TGA should down-schedule psilocybin and MDMA
Honi Soit, 26 February, 2021
The Therapeutic Goods Administration should lead the way in destigmatising psychedelics.
Demand for illegal drugs in therapy
The Australian, 21 February, 2021
After an interim decision by the health regulator rejected an application to make psilocybin and MDMA more accessible for psychiatrists to treat mental illness, patients are increasingly turning to illicit treatments.
Proposed California Law Would Legalize Magic Mushrooms, MDMA, LSD, And Other Psychedelic Drugs
Forbes, 18 February, 2021
A proposal that would allow the possession, cultivation, use, and “sharing” of most psychedelic medicines in California was formally introduced in the state Legislature on Thursday.
2021 Time100 Next: Robin Carhart-Harris
Time, 17 February, 2021
Can psychedelic drugs treat depression? That’s the promise of findings from Robin Carhart-Harris, whose research is advancing a once fringe idea.
MDMA proves a promising alcoholism treatment in world-first trial
New Atlas, 21 February, 2021
A new study published in the Journal of Psychopharmacology is reporting on a landmark clinical trial exploring the potential for MDMA-assisted psychotherapy in treating subjects with alcohol use disorder.
Young people’s despair over coronavirus deepens as crisis drags on
SMH, 15 February, 2021
With curfews, closures and lockdowns in European countries set to drag into the northern spring or even the summer, mental health professionals are growing increasingly alarmed about the deteriorating mental state of young people, who they say have been among the most badly affected by a world with a foreshortened sense of the future.
Trips out: regulator says no to ‘shrooms as treatment for mental illness
MSN, 10 February, 2021
In an interim decision published last week, the regulator refused to reschedule psilocybin and MDMA as controlled medical substances, a classification which would allow doctors to more easily prescribe them for treatment.
Psychedelic drug memo sparks uproar
The Australian, 09 February, 2021
The peak body for psychiatrists has been savaged by its own members for a “pitiful” clinical memorandum, which lay behind the health regulator’s preliminary decision not to reclassify psychedelic medicines.
Stroke victims to be given psychedelic drug DMT in groundbreaking study
Metro, 04 February, 2021
Psychedelic medicine DMT could help stroke victims recover by rewiring their brains faster, according to the first clinical trial of its kind.
Psychedelics as Antidepressants
Scientific American, 30 January, 2021
The treatments of the future may arise from a long-stigmatized class of medicines.
How ecstasy and psilocybin are shaking up psychiatry
Nature, 27 January, 2021
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Ketamine to treat depression and addiction at UK’s first medical psychedelic psychotherapy clinic
iNews, 25 January, 2021
The medicine is to be used by Awakn Life Sciences when its centre opens in Bristol in March, explains its chief medical officer Dr Ben Sessa.
Unique magic mushroom microdosing study to begin in Australia
New Atlas, 20 January, 2021
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics. The research promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging technique and a unique kind of trial protocol.
EXCLUSIVE: Florida Lawmaker Introducing Psilocybin Mushroom Legalization
Forbes, 15 January, 2021
A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
CNBC, 15 January, 2021
Headquartered in Berlin, ATAI is aiming to make psychedelic medicines that can be used to treat mental health disorders. Recognify, meanwhile, is specifically aiming to make a medicine that can be used to treat the cognitive impairment associated with schizophrenia, or CIAS.
Talking Music, Ceremony and Psychedelic-Assisted Therapy with Tania de Jong AM
Rune Soup, 13 January, 2021
Mount Sinai Health System Launches Center for Psychedelic Research
Psychedelic Finance, 08 January, 2021
New York, Ny (January 07, 2021) The Icahn School of Medicine at Mount Sinai has launched a new center for psychedelics research. The Center for Psychedelic Psychotherapy and Trauma Research pursues a multipronged clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
Globe News Wire, 08 January, 2021
Why Investors Are Psyched About Psychedelic Stocks
Visual Capitalist, 07 January, 2021
Psychedelic stocks are trading like biotechnology companies these days. The prospect of promising research has pushed valuations upwards.
Big pharma is about to tune in to the potential of psychedelics
Wired, 01 January, 2021
Mainstream mental-health care will embrace alternative active substances such as psilocybin.
Why Canada Could Be Next To Allow Psychedelic Therapy (And How It’s Already Changing Lives)
Forbes, 30 December, 2020
Now, as a handful of patients and more recently doctors and therapists have been granted exemptions to use psilocybin, the nation’s federal health agency is considering making changes to existing policies that could open the door to much more than magic mushrooms.
Psychedelic drug DMT to be trialled in UK to treat depression
The Guardian, 10 December, 2020
Exclusive: UK regulators give go-ahead for drug to be trialled ahead of possible treatment alongside psychotherapy.
New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression
UC Davis, 09 December, 2020
A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature.
Health care professionals okayed to use magic mushrooms for training in psilocybin therapy
Now Toronto, 09 December, 2020
Psychologists, psychiatrists, social workers and nurses are among 17 health care professionals granted the exemption by Health Canada this week.
Can the active ingredient in magic mushrooms help treat anxiety? Researchers want to know.
The Age, 08 December, 2020
Australia is embarking on one of the world’s largest studies into the use of psychedelic drugs for mental health, with Melbourne researchers preparing to launch a world-first clinical trial investigating whether psilocybin – the active ingredient in “magic mushrooms” – can help treat people suffering severe persistent anxiety.
Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s
Parkinson's News Today, 04 December, 2020
Silo Pharma is collaborating with Maastricht University on a Phase 2b clinical trial to investigate the effects of low-dose psychedelics on cognitive and emotional dysfunction in patients with Parkinson’s disease.
United Nations approves WHO recommendation to reschedule cannabis in historic vote
Marijuana Business Daily, 02 December, 2020
The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.
Psilocybin Treatment for Mental Health Gets Legal Framework
Scientific American, 01 December, 2020
Oregon became the first state to legalize therapeutic use of the drug, as new research affirms its benefits for treating depression.
'The war on drugs failed': California lawmaker will push to decriminalise psychedelics
The Guardian, 20 November, 2020
A California lawmaker has announced he will take on the arduous battle to decriminalize psychedelics in the state, citing Oregon, which voted to decriminalize hard drugs and legalize psilocybin, and the District of Columbia, which has decriminalized psychedelics, as inspiration.
Jewish psychedelics advocate working to turn drug into legal medicine
The Jerusalem Post, 20 November, 2020
In the United States, research on these chemicals has been banned since the 1960s because, in the government’s judgment, they have no recognized medical value.
Psilocybin for Depression Study Approved and Funded by German Government
Psilocybin Alpha, 19 November, 2020
The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.
Canada Is Allowing People With Depression to Do Psychedelic Mushrooms
Vice World News, 17 November, 2020
The Canadian government is allowing patients who are not terminally ill to legally consume psychedelic mushrooms.
What the U.S. Military’s $27M investment in psychedelic drugs could mean for veterans with PTSD
The Dales Report, 11 November, 2020
The U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) has invested nearly USD $27 million into a team of researchers led by professor of pharmacology Dr. Bryan L. Roth at the University of North Carolina School of Medicine.
Washington, DC, just decriminalized psychedelic plants. Here’s what happens next
Leafly, 04 November, 2020
Residents of the nation’s capital just took a step toward more liberal use of hallucinogens, in response to a groundswell of interest in new drugs for medical maladies.
Oregon becomes first state to legalize magic mushrooms as more states ease drug laws in ‘psychedelic renaissance’
CNBC, 04 November, 2020
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
Plos One, 14 October, 2020
Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MAPS, 14 October, 2020
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $(USD)103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients.
What if a Pill Can Change Your Politics or Religious Beliefs?
Eddie Jacobs, Scientific American, 11 October, 2020
The New Yorker: Turn On, Tune In, Get Well
The New Yorker, 12 October, 2020
New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center.
PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz
Global News Wire, 25 September, 2020
PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.
The Washington Post: Who Will Benefit From Psychedelic Medicine?
Washington Post, 21 September, 2020
Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space
Bezinga, 19 September, 2020
On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.
IntelGenx inks double deals to develop oral film psychedelics for psychiatric use
Fierce Pharma, 16 September, 2020
Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.
UC Berkeley launches center for psychedelic science and education
Berkeleyside, 18 September, 2020
UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.
Usona Puts New Psilocybin Synthesis Method in the Public Domain
Ann Harrison, 15 September, 2020
The nonprofit Usona Institute has developed a new technique to synthesize kilograms of pharmaceutical grade psilocybin and placed this information in the public domain where it cannot be patented.
Psychedelics For CNS Disorders: Understanding The Opportunity